Robert Forrester Net Worth

The estimated Net Worth of Robert Forrester is at least $614 Thousand dollars as of 27 September 2018. Robert Forrester owns over 10,500 units of Verastem Inc stock worth over $613,855 and over the last 13 years Robert sold VSTM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Robert Forrester VSTM stock SEC Form 4 insiders trading

Robert has made over 9 trades of the Verastem Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Robert bought 10,500 units of VSTM stock worth $73,500 on 27 September 2018.

The largest trade Robert's ever made was buying 10,500 units of Verastem Inc stock on 27 September 2018 worth over $73,500. On average, Robert trades about 672 units every 60 days since 2012. As of 27 September 2018 Robert still owns at least 219,234 units of Verastem Inc stock.

You can see the complete history of Robert Forrester stock trades at the bottom of the page.

What's Robert Forrester's mailing address?

Robert's mailing address filed with the SEC is C/O VERASTEM, INC.,, 117 KENDRICK STREET, SUITE 500, NEEDHAM, MA, 02494.

Insiders trading at Verastem Inc

Over the last 13 years, insiders at Verastem Inc have traded over $5,883,823 worth of Verastem Inc stock and bought 3,873,819 units worth $28,318,633 . The most active insiders traders include Capital Management, L.P.Ra ..., Christoph H Westphal, and Ansbert Gadicke. On average, Verastem Inc executives and independent directors trade stock every 28 days with the average trade being worth of $112,479. The most recent stock trade was executed by Dan Paterson on 5 August 2024, trading 3,245 units of VSTM stock currently worth $7,009.

What does Verastem Inc do?

verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com

Complete history of Robert Forrester stock trades at Immunomedics and Verastem Inc

Verastem Inc executives and stock owners

Verastem Inc executives and other stock owners filed with the SEC include:

• Brian Stuglik,
  Chief Executive Officer, Director
• Daniel Paterson,
  President, Chief Operating Officer
• Robert Gagnon,
  Chief Financial Officer, Chief Business Officer
• Brian M. Stuglik BPHARM, R.Ph., RPh,
  CEO & Director
• Brian Stuglik R.Ph., RPh,
  CEO & Director
• Daniel W. Paterson,
  COO & Pres
• Robert E. Gagnon,
  Chief Bus. & Financial Officer
• Michael Kauffman,
  Lead Independent Director
• Timothy Barberich,
  Independent Director
• Eric Rowinsky,
  Independent Director
• Alison Lawton,
  Independent Director
• Bruce Wendel,
  Independent Director
• Gina Consylman,
  Independent Director
• John Doyle,
  Investor Relations
• Dr. Michelle Dipp M.D., Ph.D.,
  Co-Founder
• Sean C. Flynn,
  VP, Gen. Counsel & Sec.
• Erin S. Cox,
  Sr. Director of Investor Relations & Corp. Communications
• Dr. Jonathan Pachter Ph.D.,
  Chief Scientific Officer
• Dr. Michelle Dipp,
  Co-Founder
• Dr. Piyush B. Gupta Ph.D.,
  Co-Founder
• Dr. Robert A. Weinberg,
  nder & Former Chair of Scientific Advisory Board
• Richard H. Aldrich M.B.A., Mba,
  Founder and Consultant
• S. Louise Phanstiel,
  Director
• Joseph Chiapponi,
  Vice President of Finance
• John B Green,
  Chief Financial Officer
• Monica Singh,
  General Counsel
• Henri A Termeer,
  Director
• Stephen A Sherwin,
  Director
• Christoph H Westphal,
  Executive Chairman
• Paul A Friedman,
  Director
• Karin Anna Tollefson,
  Director
• Steven H. Bloom,
  Chief Strategy Officer
• Julie B Feder,
  Chief Financial Officer
• Robert Forrester,
  President and CEO
• Ngoc Diep T. Md, Ph D Le,
  Chief Medical Officer
• Joseph M Lobacki,
  Executive VP & CCO
• Gregory Berk,
  Chief Medical Officer
• Capital Investments L.P.Rid...,
  
• Capital Management, L.P.Ra ...,
  
• John Johnson,
  Director
• Management Co. Llc Deer,
  Director
• Iii Lp Chp,
  10% owner
• John K Clarke,
  Director
• Joanna Horobin,
  Chief Medical Officer
• Jonathan Pachter,
  VP, Head of Research
• Fund, L.P. Longwood,
  10% owner
• Venture Partners Vii L.P.Be...,
  
• Stephen Kraus,
  Director
• Ansbert Gadicke,
  Director
• Bioventures V Llcmpm Bioven...,
  
• Piyush Gupta,
  10% owner
• Iii Lpchp Iii Management, L...,
  
• Daniel Calkins,
  Chief Financial Officer
• Frank Neumann,
  Chief Medical Officer
• Paul A. Bunn,
  Director
• Lesley Kim Solomon,
  Director
• Michelle Robertson,
  Director
• Anil Kapur,
  Director
• Dan Paterson,
  President and CEO